Introduction:
Leading pharmaceutical company has approved a ₹342 crore capital expenditure to enhance peptide manufacturing. The investment will expand reactor capacity and boost production capabilities, supporting the company’s growth strategy for both CMS and GDS customers.
Also Read: Stocks To Watch For Budget 2025
Share price movement of Neuland Laboratories:
On January 22, 2025, Neuland Laboratories Ltd. opened at ₹13,855.00, up 5.02% from its previous close of ₹13,196.05. The stock reached a high of ₹13,915.00 (3.64%) and a low of ₹13,350.00. By 12:03 PM, it traded at ₹13,676.05, a 3.64% increase, with a market cap of ₹17,546.22 crore.
Neuland Labs Approves ₹342 Crore Capex:
Neuland Laboratories Limited has approved a capital expenditure of ₹342 crore to enhance its peptide manufacturing capabilities. This investment includes ₹254 crore to expand its peptide synthesizer reactor capacity, set to scale the company’s operations at Unit-1.
The approved investment aims to increase the reactor capacity from 0.5 KL to 6.37 KL, enabling Neuland Labs to cater to both its CMS and GDS customers. The project is expected to be completed by FY27, with funding sourced through a combination of debt and internal accruals.
In addition to the peptide manufacturing expansion, the board has approved an ₹88 crore investment to boost capacity at Unit-3 by 52 KL. This new capacity is projected to come online in 15 to 18 months, supporting Neuland’s growth strategy.
Ace investor holding in Neuland Laboratories:
Mukul Mahavir Agrawal
Mukul Mahavir Agrawal holds a 3.12% stake in Neuland Laboratories Ltd., with 400,000 shares valued at ₹549.2 crore. This significant holding reflects a strong financial interest in the company’s performance and growth potential.
Siddharth Iyer
Siddharth Iyer holds a 1.73% stake in Neuland Laboratories Ltd., with 221,990 shares valued at ₹304.8 crore. This investment underscores his significant interest in the company’s operations and future prospects.
Stock performance of Neuland Laboratories for Period of 1 week, 6 months and 1 year:
Over the past week, Neuland Laboratories Ltd. has seen a decline of 1.45%. However, the company has posted an impressive 57.8% return over the last six months and a remarkable 134% increase over the past year.
Also Read: Best Sectors To Watch For Budget 2025
Shareholding pattern of Neuland Laboratories:
| All values in % | Dec 2024 | Sep 2024 | Jun 2024 |
| Promoter | 33% | 33% | 33% |
| FII | 23.90% | 26.50% | 25.70% |
| DII | 9.50% | 6.80% | 6.80% |
| Public | 34% | 34.10% | 34.80% |
About Neuland Laboratories:
Neuland Laboratories Ltd. (NSE Symbol: NEULANDLAB) specializes in manufacturing bulk drugs, including APIs and custom solutions. It operates in Prime, Niche APIs, and Custom Manufacturing Solutions segments, catering to both domestic and international markets with a focus on complex products.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
